NCT00569127 2026-03-18Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine TumorNational Cancer Institute (NCI)Phase 3 Active not recruiting427 enrolled 17 charts